TITLE

Towards an understanding of barriers to condom use in rural Benin using the Health Belief Model: A cross sectional survey

AUTHOR(S)
Hounton, Sennen H.; Carabin, Hélène; Henderson, Neil J.
PUB. DATE
January 2005
SOURCE
BMC Public Health;2005, Vol. 5 Issue 1, p8
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: HIV/AIDS is the most dramatic epidemic of the century that has claimed over two decade more than 3 million deaths. Sub Saharan Africa is heavily affected and accounts for nearly 70% of all cases. Despite awareness campaigns, prevention measures and more recently promotion of anti viral regimens, the prevalence of cases and deaths is still rising and the prevalence of systematic condom use remains low, especially in rural areas. This study identifies barriers to condom use based on the Health Belief Model (HBM) in Benin, West Africa. Methods: The study was a cross-sectional survey conducted from June to July 2002. Two hundred fifty one (251) individuals were interviewed using a structured questionnaire adapted from a standardized WHO/GAP questionnaire. A logistic regression was used to identify factors associated with condom use. Results: In spite of satisfactory knowledge on HIV/AIDS transmission, participants are still at high risk of contracting the infection. Sixty three (63) percents of the interviewees reported being able to recognize infected people, and condom use during the last occasional intercourse was declared by only 36.8% of males and 47.5% of females. Based on the HBM, failure to use condom was related to its perceived lack of efficacy [OR = 9.76 (3.71-30.0)] and perceived quality [OR = 3.61 (1.31-9.91)]. Conclusions: This study identifies perceived efficacy (incomplete protective effect) and perceived utilization-related problem (any reported problem using condoms) as the main barriers to condom use. Hence, preventions strategies based on increasing perceived risk, perceived severity or adequate knowledge about HIV/AIDS may not be sufficient to induce condom use. These data will be useful in designing and improving HIV/AIDS prevention outreach programs in Sub Saharan Africa.
ACCESSION #
29361770

 

Related Articles

  • AIDS BRIEF. Alcorn, Keith // CME: Continuing Medical Education;Jun2011, Vol. 29 Issue 6, p262 

    The article discusses research concerning the use of antiretroviral treatment for reducing risk of HIV transmission. The large randomised study involves male-female couples with one HIV-positive partner. The participants from several countries including Botswana, Brazil, and India received...

  • Lopinavir/Ritonavir: A Review of its Use in the Management of HIV Infection. Cvetkovic, Risto S.; Goa, Karen L. // Drugs;2003, Vol. 63 Issue 8, p769 

    Lopinavir is a novel protease inhibitor (PI) developed from ritonavir. Coadministration with low-dose ritonavir significantly improves the pharmacokinetic properties and hence the activity of lopinavir against HIV-1 protease. Coformulated lopinavir/ritonavir was developed for ease of...

  • CD8+ T-cell-mediated Non-cytolytic Suppression of Human Immunodeficiency Viruses. C. Vella; R.S. Daniels // Current Drug Targets - Infectious Disorders;Jun2003, Vol. 3 Issue 2, p97 

    Major Histocompatibility (MHC)-restricted Cytotoxic T-Lymphocytes (CTL) kill Human Immunodeficiency Virus (HIV)-infected cells. In addition, activated CD8+ T-lymphocytes from HIV-infected individuals suppress virus replication in vitro by producing antiviral factor (CAF). The effector...

  • HIV/AIDS: Various Issues Explored. Barton, E. N. // West Indian Medical Journal;2010 Special Issue, Vol. 59 Issue 4, p345 

    An introduction to the journal is presented in which the editor discusses various reports published within the issue including one by A. Gomez and C. Alexis-Thomas on perspectives of leaders in Grenada on the prevalence of HIV-AIDS patients, one by P. R. Byam and colleagues on the causes of...

  • In This Issue.  // Clinical Infectious Diseases;12/15/2007, Vol. 45 Issue 12, pi 

    The article discusses various reports published within the issue including one about Panton-Valentine leukocidin and another about the usage of antiretroviral therapy in HIV-infected patients with kidney disease.

  • SOFT-GEL SAQUINAVIR NOW AVAILABLE.  // AIDS Patient Care & STDs;Feb1998, Vol. 12 Issue 2, p146 

    Reports that the soft gel formulation of saquinavir (Fortovase) was approved for the market to treat human immunodeficiency virus (HIV) infection in adults in combination with other antiretroviral agents. When saquinavir was introduced to treat HIV; Reported side effects from patients receiving...

  • New Class of Medications Approved for Advanced HIV.  // FDA Consumer;May/Jun2003, Vol. 37 Issue 3, p5 

    Focuses on the advanced HIV infection medication called Fuzeon or enfuvirtide, approved by the U.S. Food and Drug Administration. Combination with other drugs; Background on the fusion inhibitor drug Type of therapy needed for effective HIV treatment.

  • Adefovir dipivoxil: A Viewpoint by Lieve Naesens & Erik De Clercq. Naesens, L.; de Clercq, E. // Drugs;Sep1999, Vol. 58 Issue 3, p488 

    Comments on a study on the HIV inhibitor drug adefovir dipivoxil. Reasons behind the failure of the development of anti-HIV drugs; Difference of adefovir dipivoxil with other HIV inhibitor; Background on the adverse effect of adefovir dipivoxil.

  • Adefovir dipivoxil: A Viewpoint by Arnold Fridland. Fridland, A. // Drugs;Sep1999, Vol. 58 Issue 3, p488 

    Discusses the use of adefovir dipivoxil in the management of HIV infection. Information on the adverse effect of the anti-viral agent; Mechanism of action; Details on the effectiveness of adefovir dipivoxil.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics